KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLoans and Notes ReceivablesLong-Term Debt IssuancesNon-Current ReceivablesReceivables RefundsShares Repurchased
Ratios

Royalty Pharma (RPRX) Receivables - Other (2019 - 2023)

Royalty Pharma (RPRX) has disclosed Receivables - Other for 5 consecutive years, with $14.2 million as the latest value for Q4 2023.

  • Quarterly Receivables - Other fell 15.38% to $14.2 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $14.2 million through Dec 2023, down 15.38% year-over-year, with the annual reading at $14.2 million for FY2023, 15.38% down from the prior year.
  • Receivables - Other hit $14.2 million in Q4 2023 for Royalty Pharma, down from $16.4 million in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $59.7 million in Q3 2021 to a low of $14.2 million in Q4 2023.
  • Historically, Receivables - Other has averaged $29.1 million across 5 years, with a median of $32.3 million in 2020.
  • Biggest five-year swings in Receivables - Other: skyrocketed 84.29% in 2021 and later tumbled 73.66% in 2022.
  • Year by year, Receivables - Other stood at $33.5 million in 2019, then fell by 1.1% to $33.2 million in 2020, then soared by 79.93% to $59.7 million in 2021, then crashed by 71.79% to $16.8 million in 2022, then dropped by 15.38% to $14.2 million in 2023.
  • Business Quant data shows Receivables - Other for RPRX at $14.2 million in Q4 2023, $16.4 million in Q3 2023, and $16.4 million in Q2 2023.